Become A Featured Company

What Revive’s PharmaTher Acquisition Means for Investors

Ryan Allway

March 24th, 2021

News, Top Story

Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) recently acquired the full rights to PharmaTher Inc.’s (CSE: PHRM) (OTC: PHRRF) intellectual property pertaining to psilocybin—the most popular psychedelic compound in clinical development worldwide.

The assets include preclinical research from the National Health Research Institutes in traumatic brain injury and stroke, as well as three key provisional patents with the U.S. Patent and Trademark Office. In aggregate, the assets were developed to target a U.S. FDA Orphan Drug Designation for psilocybin in traumatic brain injury and stroke.

“We are now in a position to advance our psilocybin program for future clinical development in various unmet medical needs in mental health, cancer and neurological diseases,” said Revive Therapeutics CEO Michael Frank. 

Let’s take a look at how the acquisition fits in with the company’s unique strategy, the significant market that the asset target and why it’s such a synergistic acquisition.

Click here to receive an investor presentation and corporate updates 

Unique Development Strategy 

Revive Therapeutics’ long-term strategy has been to take advantage of the regulatory incentives at the FDA, including its Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations to advance drugs through clinical trials. The acquisition of PharmaTher’s assets fit in with that model by targeting an Orphan Drug Designation.

The Orphan Drug Designation provides special status to a drug that is developed to treat a rare disease or condition. In exchange for developing the drug, the sponsor is eligible for tax credits worth 50% of the clinical drug testing cost and market exclusivity for seven years post approval—both lowering the cost of clinical trials and creating a barrier to entry.

Significant Unmet Medical Need

PharmaTher’s assets are also focused on large markets with significant unmet medical needs—or in other words, no effective treatment options for those suffering from the conditions. 

The market for traumatic brain injury assessment and management devices reached nearly $3 billion in 2020, according to Grand View Research, and is expected to grow at an 8.3% compound annual growth rate through 2028. The CDC estimates that TBI is responsible for 2.8 million accidents and emergency visits each year in the U.S. with few treatment options.

Despite improved assessment and management technologies, there are few effective treatment options for TBI after it occurs, leaving sufferers with impaired thinking, memory, movement, sensation or emotional function. Between 2006 and 2014, the CDC found a 53% increase in emergency room visits, hospitalizations and deaths from TBI.

Revive Therapeutics anticipates initial research results from its psilocybin for TBI program during the first quarter of the year before submitting an FDA IND for psilocybin in TBI and beginning formal clinical trials—and PharmaTher’s assets will be instrumental.

Stroke represents a much larger market at about $30 billion in 2019, according to GM Insights, while a rising geriatric population is expected to drive 6.3% compound annual growth through 2026. Despite advances in identifying strokes and limiting the damage, there are few treatment options for those that suffer from the effects of a stroke.

Click here to receive an investor presentation and corporate updates 

Synergistic Acquisition 

The PharmaTher acquisition complements Revive Therapeutics’ existing psychedelics pharmaceutical platform that includes the development of an oral thin film product, a novel biosynthesis version of psilocybin, a clinical study evaluating psilocybin for methamphetamine use disorder and research in stroke, TBI and cancer.

With an innovative pathway to market and unique delivery systems, the company is well-positioned to unlock value for shareholders over time. Investors may want to keep a close eye on the stock over the coming months as it integrates the PharmaTher assets and advances various programs into clinical development.

For more information, visit the company’s website or download their investor presentation.

Click here to receive an investor presentation and corporate updates

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading